Primary Hyperparathyroidism and Bone

Slides:



Advertisements
Similar presentations
Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.
Advertisements

How Should We Monitor, Prevent, and Treat Osteoporosis in IBD? All of Our IBD Patients are at Risk and Therefore all Should Begin Treatment at Diagnosis.
OSTEOPOROSIS An overview of the condition and its treatment
Osteoporosis Dr. Aisha Sheikh FCPS (Pak), Fellowship Diabetes/Endocrinology (AKUH), PG Dip Diab (UK) Consultant Endocrinologist.
Bone Quality PART 1 Introduction Architecture Turnover.
Bone Quality PART 3 Collagen/Mineral Matrix Conclusions Supplemental Slides.
Downloaded from 1 Alendronate vs. Risedronate Comparison Trial.
Protelos Long-Term Antifracture Efficacy. Protelos Vertebral Antifracture Efficacy over 4 years in SOTI Favors Protelos  RR P
Osteoporosis Dr. Lauren Phillips Sugar Land Women’s Health.
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
OSTEOPOROSIS Prof. Dr. Ülkü Akarırmak. Metabolic Bone Diseases Osteosclerosis Osteolysis Osteoporosis is the most common metabolic bone disease.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 75 Drugs Affecting Calcium Levels and Bone Mineralization.
Postmenopausal Osteoporosis Overview Bruce Ettinger, MD Senior Investigator Division of Research Kaiser Permanente Medical Care Program Oakland, California.
ECTS symposium 5 Anabolic treatment of osteoporosis.
Hanna Przepiera-Będzak Klinika Reumatologii PAM, Szczecin.
1 Ipriflavone in the Treatment of Postmenopausal Osteoporosis Randomized placebo-controlled, 4-year study conducted Europe 475 postmenopausal white women,
1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium... 1 Tuesday 28 Oct 2008 Hall I Session I: 8:00- 10:00 Symposium...
Focus on Endocrine Neoplasia Rome, July 9-10, 2010
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.
By Siraya Kitiyodom ปัญหาที่เกี่ยวกับสุขภาพ ที่พบบ่อยในสตรีวัยทอง และวิธีการดูแล (Part II)
June 2004 Bone Quality June 2004 A systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue,
Falls Prevention 2007 The “Challenge” May 14, 2007 Dr. M. Sugai.
Vietnam Osteoporosis Workshop, HCM Cty 2006 OSTEOPOROSIS IN MEN Tuan Van Nguyen and Nguyen Dinh Nguyen Garvan Institute of Medical Research Sydney, Australia.
What is the Bone?. Connective tissue  Organic matrix (cells & proteins)  Inorganic elements (calcium hydroxyapatite)
Internal Medicine Weekly Conference 1392 Internal Medicine Weekly Conference 1392 Alimohammad Fatemi Assistant Professor of Rheumatology Alimohammad Fatemi.
Parathyroid disorders
June 2004 Bone Quality Sourced from NIH Consensus Development Panel on Osteoporosis. JAMA 285: ; 2001 Architecture Turnover Rate Damage Accumulation.
Extended Treatment Effects with Zoledronic Acid Based on Poster 1070 “The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment in Osteoporosis: a Randomized.
Estrogen plus Progestin, BMD and Fractures: Women’s Health Initiative Jane A. Cauley University of Pittsburgh JAMA 2003; 290 (13) :
Osteoporosis Armed Forces Academy of Medical Sciences.
The Negative BMU Balance Mean wall thickness (µm)
Osteoporosis. Background ► The problem  Osteoporosis is common  Over 50% of women and 30-45% of men over age 50 have osteopenia/osteoporosis  White.
FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.
Osteoporosis Dr Ramin Rafiei Alzahra Hospital Rheumatology Department.
 Glucocorticoids  Excessive thyroid hormone  Diuretics: Furosemide  Cyclosporine, methotrexate, tacrolimus  Seizure medications: Phenytoin, phenobarbital.
Vitamin D, Rickets and Osteoporosis
Prevention and Treatment of Osteoporosis
Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures by Tamara D. Rozental, Eric C. Makhni, Charles S. Day, and Mary L.
Osteoporosis In Thalassemia Dr Tarek Jawad INT 555.
Welcome To Our Presentation
Weekly Alendronate Safe and Effective at Increasing Bone Mineral Density in HIV-Infected Persons on Antiretroviral Therapy Slideset on: McComsey GA, Kendall.
Aasis Unnanuntana, MD, MSc Case Discussion: Bone Forming Drug Associate Professor in Orthopaedic Surgery Department of Orthopaedic Surgery, Siriraj Hospital,
OSTEOPOROSIS. Characteristics of osteoporosis include a reduction of bone density and a change in bone structure, both of which increase susceptibility.
Osteopenia and Osteoporosis Bradley K. Harrison, MD.
Osteoporosis Dr Janet Horner Leeds Teaching Hospitals NHS Trust.
Chapter ?? 23 Osteoporosis Nichols and Pavlovic C H A P T E R.
Osteoporosis Ivan M ü l l e r University Hospital Brno, Orthopaedic Dept Brno-Bohunice.
Treatment of Vitamin D Insufficiency in Postmenopausal Women: A randomized clinical trial Journal Club 1/8/2016 Sharda Mukunda.
Osteoporosis. Definitions: - - Osteoblasts: Fibroblasts essential for bone formation and mineralization of bone matrix - - Osteoclasts: Cells that break.
Vitamin D and HIV Subbulaxmi Trikudanathan, MD, MRCP, MMSc
Osteopenia in Sheehan’s Syndrome
Drugs Affecting Calcium Levels and Bone Mineralization
A. Mean difference in the lumbar spine areal BMD Z-score in published, controlled trials of bisphosphonate therapy for the treatment of children with osteoporosis,
Post Menopausal Osteoporosis
Goal-directed Treatment for Osteoporosis
Fig. 1. Trial profile. From: Randomized Teriparatide [Human Parathyroid Hormone (PTH) 1–34] Once-Weekly Efficacy Research (TOWER) Trial for Examining the.
Osteoporosis Diagnosis 9/21/2018 OSTEOPOROSIS.
dr. Muh. Ardi Munir, M.Kes, Sp.OT, M.H, FICS
Case for androgens Giorgio Arnaldi Clinica di Endocrinologia
Diabetes and Bone: the model of GIO
The Roles of Bone Mineral Density, Bone Turnover, and Other Properties in Reducing Fracture Risk During Antiresorptive Therapy  Solomon Epstein, MD  Mayo.
Deciding on Pharmacological Treatment Post Fracture
Treatment Options for Osteoporosis
Vert Non-Vert Hip ** ** Zoledronic Acid3 Zoledronic Acid4 Denosumab5
Deciding on Pharmacological Treatment Post Fracture
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis 
Enrollment and Outcomes
Figure 1. Relative risks of vertebral, hip, and nonvertebral fractures (and 95% CIs) in response to the treatments for ... Figure 1. Relative risks of.
Presentation transcript:

Primary Hyperparathyroidism and Bone Jens Bollerslev Oslo University Hospital and University in Oslo, Norway

PTH in Endocrinology Metabolic Supportive

Outline PHPT and Bone Remodeling Bone Turnover in PHPT Bone Mass in PHPT Fractures in PHPT Conclusions

Bone Growth and Renewal Modeling during growth Trabecular and Cortical remodeling in adulthood Stochastic - dedicated to calcium homeostasis - under hormonal control Targeted - removal of micro-damage - essential for mechanical properties Parfitt 2002

Bone Remodeling Endocr Rev 2011

Bone Remodeling

PTH: Regulation of Bone Cell Differentiation Baron & Hesse, JCEM 2012

Reconstructed Trabecular Remodeling Eriksen, 1986 Mosekilde, 2007

3d-Reconstructed Trabecular Remodeling Dempster et al, 2007

Bone Metabolism in PHPT Biochemical: High turn-over; reversible bone loss Histomorphometry: Trabecular Bone Volume is maintained Trabecularization of Endocortical Envelope Cortical bone mass decreased Osteodensitometry: qBEI: quantitative Backscattered Electron Imaging Expected % Silverberg, JBMR, 1989 Mosekilde, Clin Endo2007

Bone Mineral Density in the Spine, Fem Bone Mineral Density in the Spine, Fem. Neck and Proximal Radius at baseline and follow-up N = 175; 115, and 95 respectively JCEM, 2009 Bollerslev, JCEM, 2007/09

BMD Z-scores in Lumbar Spine and Femoral Neck after 5 years * * P = 0.024 * P = 0.024 P = 0.027 Lundstam, JCEM 2015

Risk of Fracture in PHPT Vestergård et al, 2002

Risk of Fractures in PHPT in relation to operation Berkson’s Bias: The risk of being diagnosed with a diagnosis of PHPT would be more likely in patients who had a Fracture event than in controls, who are not submitted to a systematic plasma calcium screening Mollerup et al, 2002

Morphometric Vertebral Fractures in pm Women with Mild PHPT Vignali, JCEM 2009

Morphometric Vertebral Fractures in pm Women with Mild PHPT Vignali, JCEM 2009

Treatment options in mild PHPT Observation Surgery, the only curative treatment Vitamin D Treatment of Symptoms Calcimimetics Anti-osteoporotic drugs Bisphosphonates Estrogens/SERM’s

Prevalent Morphometric Fractures at baseline Lundstam, JCEM 2015

Prevalent and New Morphometric Fractures after 5 years Lundstam JCEM 2015

Meta-analysis of Skeletal Effects of Intervention in mild PHPT Sankaran et al, JCEM 2010

Randomized, controlled study of Vit D treatment before and after surgery 44 pts with newly diagnosed PHPT Randomized to 2800 IU vs placebo D3 daily for 26 wks before and after PTX BMD increased in LS by 2.4% prior to surgery (Vit D vs placebo) Rolighed, JCEM 2014

Randomized, controlled study of Vit D treatment before and after surgery Rolighed, JCEM 2014

Primary Hyperparathyroidism and Bone Conclusions: Bone turn-over is increased in PHPT Trabecular Bone seems to be preserved Cortical Bone loss – Trabecularization Increased Fracture Rate - even in asymptomatic, mild PHPT Surgery is curative – anti-resorptive as effective Vitamin D is of importance!

Bone Remodeling - Compartments Hauge et al, 2001; Andersen et al, 2009